Cargando…
The need for thorough phase II studies in medicines development for Alzheimer’s disease
An important factor in the universal failure in phase III trials in mild to moderate Alzheimer’s disease in the past decade is the lack of phase II clinical data prior to entering phase III, with common reliance on biomarker results alone. Conduction of two learn-confirm cycles according to the Shei...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620743/ https://www.ncbi.nlm.nih.gov/pubmed/26503107 http://dx.doi.org/10.1186/s13195-015-0153-y |